Psyence Biomedical Ltd. (PBM) News
Follow Psyence Biomedical Ltd. (PBM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Psyence Biomedical Ltd. (PBM) Secures Exclusive U.S. Ibogaine Licence via Binding Term Sheet
Psyence Biomedical said its Texas unit signed a binding term sheet with PsyLabs for exclusive U.S. licence, supply and distribution of pharmaceutical-grade ibogaine. Milestones total up to ~$1.3M for the first candidate;
NEWS | Sep 28, 2026, 11:09 AM UTC
L
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to a definitive agreementNEW Y
NEWS | Sep 28, 2026, 11:08 AM UTC
L
Psyence Biomedical Ltd. (PBM) To Invest Up To $5M In PsyLabs, Execute ~$9M Share Exchange
Psyence Biomedical Ltd. agreed to invest up to $5M in PsyLabs and a reciprocal ~$9M share-for-share exchange to support a planned U.S. ibogaine program in Texas, subject to approvals and conditions.Material DetailsContex
NEWS | Sep 23, 2026, 11:03 AM UTC
L
Psyence BioMed Announces Strategic Ibogaine Investment
Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchangeHighlightsNEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. NASDAQ:PBM
NEWS | Sep 23, 2026, 11:03 AM UTC
L
PBM - Psyence BioMed Announces Strategic Ibogaine Investment
PBM - Psyence BioMed Announces Strategic Ibogaine Investment
NEWS | Sep 23, 2026, 11:00 AM UTC
L
As Trump backs psychedelics research, FDA weighs safety and access standards
By Nancy LapidThe U.S. FDA heard calls for clear safety and access standards for psychedelic therapies at a public meeting, the latest step in the Trump administration's push to speed development of treatments such as ib
REGULATION | Sep 15, 2026, 03:16 PM UTC
L
Aurwest Resources completes Phase 1 exploration at Weaver Lake
Aurwest Resources completed its Phase 1 exploration program at the Weaver Lake gold project.
COMMODITIES | Aug 27, 2026, 12:01 PM UTC
L
Psyence BioMed welcomes U.S. action to speed ibogaine development
Psyence BioMed says it welcomes the U.S. administration’s latest action to accelerate ibogaine development.
REGULATION | Aug 18, 2026, 09:23 PM UTC